REFERENCES
- Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant. 2006; 21: 1104–1108
- Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: Suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006; 17: 2359–2362
- Thomsen HS, European Society of Urogenital Radiology (ESUR). ESUR guideline: Gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol. 2007; 17: 2692–2696
- http://www.icnfdr.org, Cowper SE. The International Center for Nephrogenic Fibrosing Dermopathy Research (ICNFDR) Web site, 2001–2008
- Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006; 15(145)247–254
- Runge VM. Safety of approved MR contrast media for intravenous injection. J Magn Reson Imaging. 2000; 12: 205–213
- Townsend RR, Cohen DL, Katholi R, et al. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency. Am J Kidney Dis. 2000; 36: 1207–1212
- Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000; 356: 1000–1001
- Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: Report of a new case with literature review. Am J Kidney Dis. 2005; 46: 754–759
- Gibson SE, Farver CF, Prayson RA. Multiorgan involvement in nephrogenic fibrosing dermopathy: An autopsy case and review of the literature. Arch Pathol Lab Med. 2006; 130: 209–212
- Michaely HJ, Herrmann KA, Nael K, Oesingmann N, Reiser MF, Schoenberg SO. Functional renal imaging: Nonvascular renal disease. Abdom Imaging. 2007; 32: 1–16
- Nikken JJ, Krestin GP. MRI of the kidney-state of the art. Eur Radiol. 2007; 17: 2780–2793
- Lee VS, Kaur M, Bokacheva L, et al. What causes diminished corticomedullary differentiation in renal insufficiency?. J Magn Reson Imaging. 2007; 25: 790–795
- Namimoto T, Yamashita Y, Mitsuzaki K, Nakayama Y, Tang Y, Takahashi M. Measurement of the apparent diffusion coefficient in diffuse renal disease by diffusion-weighted echo-planar MR imaging. J Magn Reson Imaging. 1999; 9: 832–837
- Toyoshima S, Noguchi K, Seto H, Shimizu M, Watanabe N. Functional evaluation of hydronephrosis by diffusion-weighted MR imaging. Acta Radiologica. 2000; 41: 642–646
- Thoeny HC, De Keyzer F, Oyen RH, Peeters RR. Diffusion-weighted MR imaging of kidneys in healthy volunteers and patients with parenchymal diseases: Initial experience. Radiology. 2005; 235: 911–917
- Tondini C, Ferreri AJ, Siracusano L, et al. Diffuse large-cell lymphoma of the testis. J Clin Oncol. 1999; 17: 2854–2858
- Stasi R, Zinzani L, Galieni P, et al. Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure. Cancer. 1994; 74: 1792–1800
- Saito W, Amanuma M, Tanaka J, Heshiki A. A case of testicular malignant lymphoma with extension to the epididymis and spermatic cord. Magn Reson Med Sci. 2002; 1: 59–63